Intervacc’s developmental program for new vaccines against animal infectious diseases is summarised in the following table. Please, click on respective project name or indication to read more.

ProjectDisease areaSpeciesPreclinicalClinical RegulatoryMarket
INV274Strep. suis infectionPiglets
INV412Staph. aureus mastitisCow

The successful  clinical trials with vaccination against strangles using Strangvac®, based on fusions of recombinant proteins, demonstrates that our technology can be applied also for development of other vaccines. In contrast to conventional vaccines, using attenuated live strains, our technology using recombinant proteins as antigens results in a safe and efficacious vaccine with very low incidence of unwanted side effects.